Literature DB >> 1798276

Oxidation of LDL: role in atherogenesis.

H F Hoff1, J A O'Neil.   

Abstract

Oxidation of LDL is proposed to accelerate atherogenesis by the following sequence of events. LDL accumulates in atherosclerotic plaques, presumably due to interaction with intimal proteoglycans. The LDL then undergoes oxidation, and aldehydic products of lipid peroxidation such as HNE or other aldehyde products derived from lipid peroxidation, induce blocking of lysine residues on apo B. This results in its recognition by the scavenger receptor on tissue macrophages at sites in which LDL concentrations are low. At sites in which the LDL concentration is high, modification with such products induces intermolecular cross-linking and particle aggregation. The aggregated, oxidized LDL particles are then phagocytosed by tissue macrophages to induce lipid loading of these cells and the formation of foam cells, a characteristic of the earliest atherosclerotic lesion. By these mechanisms oxidation of LDL accelerates atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1798276     DOI: 10.1007/BF01645153

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  27 in total

Review 1.  Role of oxidatively modified LDL in atherosclerosis.

Authors:  U P Steinbrecher; H F Zhang; M Lougheed
Journal:  Free Radic Biol Med       Date:  1990       Impact factor: 7.376

2.  Apo B concentration in the normal human aorta.

Authors:  H F Hoff; J W Gaubatz; A M Gotto
Journal:  Biochem Biophys Res Commun       Date:  1978-12-29       Impact factor: 3.575

Review 3.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

4.  Characterization of the adhesion of the human monocytic cell line U937 to cultured endothelial cells.

Authors:  P E DiCorleto; C A de la Motte
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

5.  Ultrastructural localization of apolipoprotein B in human aortic and coronary atherosclerotic plaques.

Authors:  H F Hoff; J W Gaubatz
Journal:  Exp Mol Pathol       Date:  1977-04       Impact factor: 3.362

Review 6.  Recent advances in molecular pathology. Carbohydrate-protein macromolecules and arterial wall integrity--a role in atherogenesis.

Authors:  G S Berenson; B Radhakrishnamurthy; S R Srinivasan; P Vijayagopal; E R Dalferes; C Sharma
Journal:  Exp Mol Pathol       Date:  1984-10       Impact factor: 3.362

7.  A low density lipoprotein-sized particle isolated from human atherosclerotic lesions is internalized by macrophages via a non-scavenger-receptor mechanism.

Authors:  R E Morton; G A West; H F Hoff
Journal:  J Lipid Res       Date:  1986-11       Impact factor: 5.922

8.  Cholesterol esterification in macrophages. Stimulation by lipoproteins containing apo B isolated from human aortas.

Authors:  B A Clevidence; R E Morton; G West; D M Dusek; H F Hoff
Journal:  Arteriosclerosis       Date:  1984 May-Jun

9.  Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation.

Authors:  H F Hoff; J O'Neil
Journal:  Arterioscler Thromb       Date:  1991 Sep-Oct

10.  Macrophage uptake of low-density lipoprotein modified by 4-hydroxynonenal. An ultrastructural study.

Authors:  H F Hoff; T B Cole
Journal:  Lab Invest       Date:  1991-02       Impact factor: 5.662

View more
  2 in total

1.  Effect of oxidized low-density lipoprotein concentration polarization on human smooth muscle cells' proliferation, cycle, apoptosis and oxidized low-density lipoprotein uptake.

Authors:  Zufeng Ding; Shijie Liu; Bo Yang; Yubo Fan; Xiaoyan Deng
Journal:  J R Soc Interface       Date:  2011-11-02       Impact factor: 4.118

Review 2.  Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).

Authors:  Yukio Ando
Journal:  Med Mol Morphol       Date:  2005-09       Impact factor: 2.309

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.